Objective: The aim of this paper is to provide a brief update review of current pharmacological agents used to treat women with urge incontinence. Design: Review article. Settings: Gynecological and Obstetric Clinic, 1. LF UK and VFN, Prague. Results: Urge urinary incontinence is the condition characterized by the involuntary loss of urine accompained by a strong desire to void. Urge incontinence is often due to detrusor instability, although the instability of the detrusor bladder muscle cannot be demonstrated clinically but through cystomery. Sensory urge incontinence is the involuntary loss of urine associated with urgency and a strong desire to void urine immediately due to the hypersensitivity of the bladder and urethral sensory receptors. The mainstay treatment for this common form of incontinence is conservative treatment. There are two forms of conservative treatment: behavioural techniques and pharmacotherapy. The urge urinary incontinence is most successfully treated by a drug therapy. Anticholinergic drugs and anticholinergic antispasmodic drugs are the primary pharmacologic treatment for this condition, although the usefulness of this agent has been limited by a lack of selectivity for the bladder, which gives rise to frequent, bothersome side effect (dry mouth, constipation, blurred vision, etc.) For these reasons, tolterodine was developed as the first antimuscarinic agent specifically targeted for the treatment of the urge urinary incontinence. This agent has demonstrated a bladder-selective profile in vivo, leading to a more pronunced and longer lasting effect on the bladder than on salivation in humans.

        Key words: female urinary incontinence, urge urinary incontinence, tolterodine